Intuitive Surgical Inc. Stock Buy Recommendation Reiterated (ISRG)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Intuitive Surgical (Nasdaq: ISRG) has been reiterated by TheStreet Ratings as a buy with a ratings score of B. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, impressive record of earnings per share growth, compelling growth in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Highlights from the ratings report include:
  • The revenue growth came in higher than the industry average of 1.4%. Since the same quarter one year prior, revenues rose by 23.5%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • ISRG has no debt to speak of therefore resulting in a debt-to-equity ratio of zero, which we consider to be a relatively favorable sign. Along with this, the company maintains a quick ratio of 4.51, which clearly demonstrates the ability to cover short-term cash needs.
  • INTUITIVE SURGICAL INC has improved earnings per share by 30.3% in the most recent quarter compared to the same quarter a year ago. The company has demonstrated a pattern of positive earnings per share growth over the past two years. We feel that this trend should continue. During the past fiscal year, INTUITIVE SURGICAL INC increased its bottom line by earning $15.96 versus $12.30 in the prior year. This year, the market expects an improvement in earnings ($17.90 versus $15.96).
  • The net income growth from the same quarter one year ago has significantly exceeded that of the S&P 500 and the Health Care Equipment & Supplies industry. The net income increased by 31.6% when compared to the same quarter one year prior, rising from $143.50 million to $188.90 million.
  • Net operating cash flow has significantly increased by 54.95% to $258.00 million when compared to the same quarter last year. In addition, INTUITIVE SURGICAL INC has also vastly surpassed the industry average cash flow growth rate of -28.40%.

Intuitive Surgical, Inc. designs, manufactures, and markets da Vinci surgical systems, and related instruments and accessories. Intuitive Surgical has a market cap of $19.5 billion and is part of the health care sector and health services industry. The company has a P/E ratio of 29.00, above the S&P 500 P/E ratio of 18.00. Shares are down 0.9% year to date as of the close of trading on Wednesday.

You can view the full Intuitive Surgical Ratings Report or get investment ideas from our investment research center.

--Written by a member of TheStreet Ratings Staff.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.
null

If you liked this article you might like

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Five Rules for This Market Beast: Cramer's 'Mad Money' Recap (Tues 1/16/18)

Warren Buffett Has $100 Billion to Spend, What's He Going to Buy?

Warren Buffett Has $100 Billion to Spend, What's He Going to Buy?

The Method to My Investing Madness: Cramer's 'Mad Money' Recap (Tues 12/26/17)

The Method to My Investing Madness: Cramer's 'Mad Money' Recap (Tues 12/26/17)

CVS Health, Intuitive Surgical, Allergan: 'Mad Money' Lightning Round

CVS Health, Intuitive Surgical, Allergan: 'Mad Money' Lightning Round

Long Live the FAANNG Stocks: Cramer's 'Mad Money' Recap (Tuesday 12/19/17)

Long Live the FAANNG Stocks: Cramer's 'Mad Money' Recap (Tuesday 12/19/17)